Drugs / RST-001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT02556736 | Dec 2015 → Jun 2020 | retinitis pigmentosa | AbbVie | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | RST-001 | “AGN-151597 (formerly RST-001) administered as a single intravitreal injection” NCT02556736 ↗ |
| Known as | AGN-151597 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02556736 ↗ |
| Modality | Gene therapy (AAV / viral vector) | “AGN-151597 is a gene therapeutic delivered by intravitreal injection” NCT02556736 ↗ |
| Route | Intravitreal | “administered as a single intravitreal injection” NCT02556736 ↗ |